Literature DB >> 11550302

Morphologic and molecular genetic aspects of oligodendroglial neoplasms.

S H Bigner1, B K Rasheed, R Wiltshire, R E McLendon.   

Abstract

Morphologic criteria for diagnosing oligodendrogliomas and for classifying them as well-differentiated (World Health Organization grade II) and anaplastic (World Health Organization grade III) are well recognized. Nevertheless, applying these guidelines to specific cases often reveals discrepancies among different observers. In addition, whether a given tumor also contains an astrocytic component may be debatable. Loss of heterozygosity studies have demonstrated that oligodendroglial neoplasms have a high incidence of loss of the 1p and 19q chromosomal arms. Although loss of heterozygosity for portions of 19q are sometimes seen in astrocytic neoplasms, these tumors seldom show complete loss of 19q accompanied by loss of 1p. Loss of 9p or homozygous deletion of the CDKN2 gene or both are associated with anaplastic oligodendrogliomas, whereas loss of 17p or TP53 gene mutations or both are frequent in astrocytomas, but rare in oligodendrogliomas. These observations suggest that molecular genetic parameters could provide an objective, reproducible framework for classifying oligodendroglial neoplasms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11550302      PMCID: PMC1919462          DOI: 10.1093/neuonc/1.1.52

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  10 in total

Review 1.  Molecular pathogenesis of oligodendroglial tumors.

Authors:  Judith W M Jeuken; Andreas von Deimling; Pieter Wesseling
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

2.  Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy.

Authors:  S Chawla; J Krejza; A Vossough; Y Zhang; G S Kapoor; S Wang; D M O'Rourke; E R Melhem; H Poptani
Journal:  AJNR Am J Neuroradiol       Date:  2013-01-31       Impact factor: 3.825

3.  IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.

Authors:  Lynette M Moore; Kristen M Holmes; Sarah M Smith; Ying Wu; Elena Tchougounova; Lene Uhrbom; Raymond Sawaya; Janet M Bruner; Gregory N Fuller; Wei Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-16       Impact factor: 11.205

Review 4.  Autocrine PDGF stimulation in malignancies.

Authors:  Carl-Henrik Heldin
Journal:  Ups J Med Sci       Date:  2012-05       Impact factor: 2.384

5.  Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.

Authors:  German Reyes-Botero; Caroline Dehais; Ahmed Idbaih; Nadine Martin-Duverneuil; Marion Lahutte; Catherine Carpentier; Eric Letouzé; Olivier Chinot; Hugues Loiseau; Jerome Honnorat; Carole Ramirez; Elisabeth Moyal; Dominique Figarella-Branger; François Ducray
Journal:  Neuro Oncol       Date:  2013-12-18       Impact factor: 13.029

6.  Genetic and epigenetic stability of oligodendrogliomas at recurrence.

Authors:  Koki Aihara; Akitake Mukasa; Genta Nagae; Masashi Nomura; Shogo Yamamoto; Hiroki Ueda; Kenji Tatsuno; Junji Shibahara; Miwako Takahashi; Toshimitsu Momose; Shota Tanaka; Shunsaku Takayanagi; Shunsuke Yanagisawa; Takahide Nejo; Satoshi Takahashi; Mayu Omata; Ryohei Otani; Kuniaki Saito; Yoshitaka Narita; Motoo Nagane; Ryo Nishikawa; Keisuke Ueki; Hiroyuki Aburatani; Nobuhito Saito
Journal:  Acta Neuropathol Commun       Date:  2017-03-07       Impact factor: 7.801

7.  Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.

Authors:  Dominique Figarella-Branger; Karima Mokhtari; Caroline Dehais; Anne Jouvet; Emmanuelle Uro-Coste; Carole Colin; Catherine Carpentier; Fabien Forest; Claude-Alain Maurage; Jean-Michel Vignaud; Marc Polivka; Emmanuelle Lechapt-Zalcman; Sandrine Eimer; Gabriel Viennet; Isabelle Quintin-Roué; Marie-Hélène Aubriot-Lorton; Marie-Danièle Diebold; Delphine Loussouarn; Catherine Lacroix; Valérie Rigau; Annie Laquerrière; Fanny Vandenbos; Sophie Michalak; Henri Sevestre; Michel Peoch; François Labrousse; Christo Christov; Jean-Louis Kemeny; Marie-Pierre Chenard; Danchristian Chiforeanu; François Ducray; Ahmed Idbaih
Journal:  Neuro Oncol       Date:  2014-04-09       Impact factor: 13.029

8.  Simultaneous analysis of distinct Omics data sets with integration of biological knowledge: Multiple Factor Analysis approach.

Authors:  Marie de Tayrac; Sébastien Lê; Marc Aubry; Jean Mosser; François Husson
Journal:  BMC Genomics       Date:  2009-01-20       Impact factor: 3.969

9.  ImmunoFISH is a reliable technique for the assessment of 1p and 19q status in oligodendrogliomas.

Authors:  Céline Duval; Marie de Tayrac; François Sanschagrin; Karine Michaud; Peter Vincent Gould; Stéphan Saikali
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

10.  Three-Dimensional Nuclear Telomere Profiling as a Biomarker for Recurrence in Oligodendrogliomas: A Pilot Study.

Authors:  Macoura Gadji; Shubha Mathur; Brigitte Bélanger; Jaganmohan Reddy Jangamreddy; Josée Lamoureux; Ana Maria Crous Tsanaclis; David Fortin; Régen Drouin; Sabine Mai
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.